DailyIQ
Last updated1 minute ago

A·Agilent Technologies, Inc.

$174.97
+3.37 (+1.96%)
High
$175.54
Open
$172.19
Market Cap
48.26B
52W High
$177.05
Low
$171.50
P. Close
$174.97
P/E
33.51
52W Low
$108.35
Fwd P/E
25.40
DailyIQ Est.
$182.98
Inst. Ownership
42.0%
Short Interest
1.86%
Days to Cover
1.8
Div. Yield
0.59%
Next Ex-Div
~Jan 5
Div. Growth
13+ yrs
NewEarnings release, scored · filed Aug 26, 2026Guidance raised · tone +0.8 vs prior release · 28 lines scoredSee the breakdown
Technical Score (1D)
43
BEARISH
News Sentiment
78
BULLISH
On Oct 13, Agilent announced it would acquire Proscia in an all‑cash transaction valued at $1.2 billion. The acquisition was said to broaden Agilent’s digital pathology portfolio. It was expected to strengthen Agilent’s presence in the oncology diagnostics market. Proscia’s platform was anticipated to integrate with Agilent’s existing analytical instruments. The deal was viewed as a strategic move to capture growing demand for AI‑driven pathology solutions. The announcement highlighted the company’s intent to create cross‑sell opportunities.
LOW TARGET
$155 -11.4%
2 analysts
MEAN TARGET
$179 +2.5%
17 analysts
HIGH TARGET
$195 +11.4%
13 analysts
PRICE RANGE
$155.00 - $195.00
SB / B / H / S / SS
8/15/7/1/1
DAILYIQ EST.
$182.98 (+4.6%)
Sector
Healthcare
Industry
Diagnostics & Research
Exchange
NYQ
Country
United States
Symbol
A
Description
Agilent Technologies is a global provider of application-focused solutions for the life sciences, diagnostics, and applied chemical markets. The company operates through three primary segments: Life Sciences and Diagnostics, Agilent CrossLab, and Applied Markets. Agilent's Life Sciences and Diagnostics segment offers advanced instrumentation and related services for genomics, pathology, and biomolecular analysis, among other areas. The Agilent CrossLab segment provides a comprehensive suite of services, including instrument maintenance, software solutions, and laboratory supplies, supporting customers' operational efficiency. Finally, the Applied Markets segment delivers products in areas such as gas chromatography and spectroscopy, catering to diverse scientific applications. Agilent distributes its offerings through a multi-channel approach, including direct sales and partnerships, ensuring broad market access.
Bought (1Y)
0 shares
$0
Sold (1Y)
2,682 shares
$374K
Boehnlein Glenn S-
Award/Grant817 shares2026-09-08
Dolsten Mikael-
Sell634 shares2026-09-04
KIRKWOOD JONAH PREVOSTSenior Vice President
Tax Withholding30 shares2026-06-26
MCDONNELL PADRAIGPresident and CEO
Tax Withholding418 shares2026-06-03
Dolsten Mikael-
Sell1,600 shares2026-05-29
75/ 100
Bullish
Overall: Bullish
✓Revenue growing year over year
✓Positive net margin
✓Positive operating cash flow
Net Margin
18.8%
Revenue CAGR
1.4%
Current Ratio
1.96x
Debt / Equity
0.50x
Return on Equity
19.3%
Earnings Summary
Agilent Technologies is a global provider of application-focused solutions for the life sciences, diagnostics, and applied chemical markets, operating through Life Sciences and Diagnostics, Agilent CrossLab, and Applied Markets segments. The company serves a broad scientific customer base, delivering advanced instrumentation, services, and consumables that support genomics, pathology, and chemical analysis. In the highly competitive diagnostics and research sector, Agilent leverages its multi‑channel distribution to maintain market access and drive incremental revenue. Recent quarterly performance shows a steady upward trajectory: Q4 2024 EPS of $1.31 beat the $1.27196 estimate, while Q1 2025 EPS of $1.31 also surpassed the $1.26428 estimate; Q2 2025 EPS of $1.37 narrowly beat the $1.36772 estimate, and Q3 2025 EPS of $1.59 exceeded the $1.58408 estimate. Revenue grew from $1.681B in Q4 2024 to $1.861B in Q3 2025, a 10.8% YoY increase, and continued to rise to $1.838B in Q1 2026 before a slight dip to $1.835B in Q2 2026, matching the $1.835B estimate. The company has consistently beat earnings estimates in four of the last five quarters, with revenue growth maintained even when EPS margins fluctuated. Historically, Agilent has shown a YoY revenue growth trajectory of roughly 8–12% over the past three years, with EPS growth outpacing revenue in most periods, indicating efficient cost management. Recent news highlights analyst optimism: Barclays upgraded the price target to $195 from $175 on October 6 and 7, citing confidence in the earnings outlook and product pipeline, while analysts noted a 52.5% share price rally over three years and a 33.1‑times P/E ratio, questioning valuation justification.

EPS

EstBeatMiss
$1.20$1.34$1.49$1.64$1.78Q1'25Q2'25Q3'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$1.71 - -
Q2'26$1.44$1.49+3.8%
Q1'26$1.40$1.36-2.6%
Q3'25$1.58$1.59+0.4%
Q2'25$1.37$1.37+0.2%
Q1'25$1.26$1.31+3.6%

Revenue

EstBeatMiss
$1.6B$1.7B$1.8B$1.9B$2.0BQ1'25Q2'25Q3'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$2.0B - -
Q2'26$1.8B$1.8B+0.0%
Q1'26$1.8B$1.8B-2.4%
Q3'25 - $1.9B -
Q2'25 - $1.7B -
Q1'25 - $1.7B -

Market Data

A Stock Snapshot

NEUTRAL43/100
$174.97+$3.37 (2.0%)
Market cap
48.26B
P/E ratio
33.5
Day range
$171.50 – $175.54
News sentiment
78/100 · Bullish
Analyst target
$179.25 (+2.4%)
Consensus
Buy · 32 analysts
52-week range+61.5% off low · -1.2% from high
$108.35$177.05
Price $174.97 DailyIQ Est. $182.98

A is in a holding pattern - neither trend nor momentum has taken control. Institutional coverage is thorough here, so shifts in analyst expectations show up in price quickly.

Reverse DCF

What growth is priced into A?

RICH

At today's price, Agilent Technologies, Inc. needs to grow free cash flow about 31.6% a year for the next 10 years to justify its valuation at a 9.79% cost of capital. Over its actual history it has compounded free cash flow at 4.7% a year, so the market is asking for 26.9 percentage points above its own delivered rate. On that basis A looks priced above what its own growth record supports.

Implied FCF growth
31.6%
Historical FCF CAGR
4.7%
Growth gap
+26.9 pts
Verdict
RICH
Discount rate (WACC)
9.79%
Beta
1.00

Behaviour On Record

What A's own history says about today's numbers

Realized volatility (21d)
31.8% 79th pct
Below its peak
-4.4%
vs 200-day average
+27.9%
Up days (1y)
53%

Agilent Technologies, Inc. is currently running 31.8% annualised volatility over the last 21 sessions. Measured against A's own 13 years of daily returns rather than a market-wide average, that is the 79th percentile — elevated for this stock, against a typical reading of 24.3%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

A is trading -4.4% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -22.2%, and the deepest was -38.2% in 2023. The current pullback is therefore shallower than what this stock gives back in a typical year, which is context worth having before treating it as a dislocation.

Price sits +27.9% from its 200-day moving average. Against every other day in its history, that gap ranks at the 99th percentile — a wider gap than this stock usually carries. Over the past year A closed higher on 53% of sessions, and it is currently 1 session into a falling streak.

On October specifically: over 14 years of records, A finished the month higher 8 of 14 times, with a median return of +0.9% and an average of +0.1%. Its strongest month historically has been November at +6.5% on average, its weakest February at -2.7%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: A has opened more than 2% away from the prior close in 112 of 3,267 sessions (3.4% of the time), with the largest gaps running +10.5% and -26.7%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

Across the last 3 dated reports on file, A moved an average of 3.7% in the session after earnings, closing higher 1 of those 3 times, with a median move of -0.2% and a largest of +9.4%.

All figures computed from 3,268 daily closes between 2013-10-15 and 2026-10-14, split-adjusted, recomputed daily. Percentiles are against A's own 13-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of A's sector?

Agilent Technologies, Inc. sits in the Health Care sector, currently ranked 4th of 12 GICS sectors by relative-strength rotation score (improving).

Sector rank
#4 of 12
Sector state
Improving
Sector rotation score
73

Options Market

What is the options market pricing for A?

CallsPuts

For Agilent Technologies, Inc.'s nearest expiry (2026-10-16, 2 days out), open interest is put-heavy, a defensive/bearish tilt (put/call ratio of 1.34), with at-the-money implied volatility around 6.3%. The options market is pricing roughly a ±0.5% move by that expiry — a range of about $172.17–$173.77.

Put/call ratio (2026-10-16)
1.34
ATM implied volatility
6.3%
Total open interest
13,528
Expected move by 2026-10-16
±0.5% ($172.17–$173.77)

Analyst Rating Changes

Are analysts turning bullish or bearish on A?

TD Cowen most recently reiterated its rating on Agilent Technologies, Inc. to Buy on Oct 13, 2026 with a price target of $196 (from $180). Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.

Latest action
TD Cowen — Buy
90-day upgrades
0
90-day downgrades
0
Net rating momentum
0
DateFirmActionRatingPrice target
Oct 13, 2026TD CowenMaintainedBuy$180 → $196
Oct 13, 2026Morgan StanleyMaintainedOverweight$175 → $190
Oct 7, 2026BarclaysMaintainedOverweight$175 → $195
Aug 28, 2026Wells FargoMaintainedOverweight$160 → $180
Aug 27, 2026StifelMaintainedBuy$170 → $180
Aug 27, 2026B of A SecuritiesMaintainedBuy$155 → $180
Aug 27, 2026CitigroupMaintainedBuy$185 → $190
Aug 27, 2026Goldman SachsMaintainedBuy$155 → $175
Aug 27, 2026JP MorganMaintainedOverweight$180 → $190
Aug 27, 2026TD CowenMaintainedBuy$155 → $180
Aug 27, 2026BernsteinMaintainedOutperform$155 → $180
Aug 27, 2026RBC CapitalMaintainedOutperform$155 → $185

Earnings Release, Scored

What did Agilent Technologies, Inc.'s latest earnings release say?

Filed Aug 26, 2026 · SEC Form 8-K, Exhibit 99

Guidance raised
Tone83.3/ 100+0.8 vs prior release
Hedging words0.38per 100 words+0.18 vs prior release
Tone, last 2 releasesScale 50–89

Most important lines

  1. 1

    Non-GAAP fiscal year 2026 operating margin expansion (2) at the midpoint of core revenue growth guidance is now expected to be over 130 basis points (including approximately 30 basis points in net benefit from tariff refunds in the third quarter).

    Guidance raised
  2. 2

    Non-GAAP fiscal year 2026 EPS (4) is now expected in the range of $6.18 to $6.21, an increase of 15 cents at the midpoint (including $0.06 net benefit from tariff refunds in the third quarter) versus our prior guide.

    Guidance raised
  3. 3

    Fiscal year 2026 revenue is now expected in the range of $7.49 billion to $7.51 billion, representing a range of up 7.8% to 8.1% reported and up 5.8% to 6.0% core, (1)(5) an increase of 65 basis points at the midpoint.

    Guidance raised

Peers & ETF holders

A peers & ETF holders

News Sentiment Analysis

Sentiment gathered from recent headlines

78/100
Strong NegativeNeutralStrong Positive
BULLISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles
What did this article say?
Agilent Technologies, ticker A, announced on October 13 that it would acquire Proscia in an all‑cash transaction valued at $1.2 billion. The deal positions Agilent to broaden its digital pathology portfolio and strengthen its presence in the oncology diagnostics market. Proscia’s platform is expected to integrate with Agilent’s existing analytical instruments, creating cross‑sell opportunities. The acquisition is viewed as a strategic move to capture growing demand for AI‑driven pathology solutions.
What did this article say?
On October 13, 2026, Agilent Technologies Inc. (A) finalized a definitive agreement to acquire Proscia, a provider of digital pathology software, in an all‑cash transaction worth $240 million with an additional $30 million contingent on performance milestones. The acquisition strengthens Agilent’s AI‑enabled scientific intelligence capabilities and positions it to capture a larger share of the clinical diagnostics market. The deal is anticipated to create new revenue opportunities and accelerate product development in digital pathology.
What did this article say?
Agilent Technologies has posted a strong share price run, but analysts are questioning whether the current valuation is supported by the company’s cash generation. Recent plans to invest in a new Boulder laboratory for oligonucleotide manufacturing and the NovoStation automated sample preparation system could affect future cash flows through growth potential and capital spending. The company’s 3‑year return of 52.5% highlights the need to assess whether cash flow can sustain the price appreciation. Investors are evaluating how these projects will impact intrinsic value based on projected cash flows.
What did this article say?
Evercore ISI increased its price target for Agilent Technologies (A) from $148 to $178, reflecting a bullish outlook. The rating remains overweight, indicating confidence in the company’s future earnings. The adjustment signals analysts expect stronger revenue growth and margin expansion in the coming years.
What did this article say?
Barclays analyst Luke Sergott maintained an Overweight rating on Agilent Technologies (NYSE:A) and raised the price target from $175 to $195. The upgrade signals confidence in the company’s growth prospects and earnings outlook. The new target reflects expectations of stronger revenue and margin performance in the coming quarters.
What did this article say?
Barclays increased its price target for Agilent Technologies (A) from $175 to $195 while keeping an overweight rating. The upgrade reflects confidence in the company’s earnings outlook and product pipeline. The new target suggests a potential upside of roughly 11% from the previous estimate. This adjustment signals a bullish stance from a major research house, reinforcing positive sentiment around A’s valuation.
What did this article say?
Agilent Technologies (NYSE:A) achieved an average annual return of 14.43% over the past 15 years, outperforming the market by 1.05% on an annualized basis. The company’s market capitalization has grown steadily, reflecting sustained investor confidence. This historical performance underscores Agilent’s strong position in the life‑science and diagnostics sector. The data highlights the company’s ability to generate consistent returns for shareholders over a long period. No immediate catalysts or guidance changes were noted in the report.
What did this article say?
Agilent Technologies Inc. (NYSE: A) announced the NovoStation Sample Preparation System on Oct 1, 2026. The platform automates flow cytometry sample preparation, integrating with NovoCyte cytometers and NovoExpress software. It offers a hands‑free sample‑to‑answer workflow, reducing preparation time for laboratories. The launch positions A as a provider of end‑to‑end flow cytometry solutions. The system is expected to enhance productivity in research and clinical labs.

Technical Analysis

Real-time indicators across multiple timeframes

43
NEUTRAL
Momentum rank against about 1,000 stocks and ETFs for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Institutional & Hedge Fund Ownership
25 tracked managers · $15.71B combined position · 13 adding, 12 trimming, 0 unchanged (latest 13F filings)
ManagerTrendShares Held% of Co.Position ValueFiled
Vanguard Group Inc▲ Buy34,105,78312.12%$4.64B2026-01-29
BlackRock, Inc.▼ Sell25,599,0019.10%$3.40B2026-08-07
Geode Capital Management, LLC▲ Buy7,595,6442.70%$1.00B2026-08-12
Wellington Management Group LLP▲ Buy7,454,6862.65%$990.21M2026-08-14
Morgan Stanley▲ Buy5,185,7381.84%$688.82M2026-08-13
FMR LLC (Fidelity)▲ Buy5,076,1671.80%$674.27M2026-08-13
Goldman Sachs Group Inc▲ Buy4,707,7201.67%$625.33M2026-08-14
Norges Bank▼ Sell3,869,5441.38%$513.99M2026-08-12
Northern Trust Corp▼ Sell3,691,9411.31%$490.40M2026-08-13
AQR Capital Management LLC▲ Buy3,600,5601.28%$472.36M2026-08-14
Invesco Ltd.▲ Buy2,843,2531.01%$377.67M2026-08-14
JPMorgan Chase & Co▼ Sell2,309,3680.82%$306.75M2026-08-12
Glenview Capital Management, LLC▲ New1,969,5410.70%$261.61M2026-08-14
Bank of America Corp▼ Sell1,605,5760.57%$213.27M2026-08-14
D. E. Shaw & Co., Inc.▼ Sell1,486,1870.53%$197.41M2026-08-14
Man Group plc▲ Buy1,349,5230.48%$179.26M2026-08-14
William Blair Investment Management, LLC▼ Sell1,287,2650.46%$170.99M2026-08-12
Citadel Advisors LLC▼ Sell1,101,5010.39%$146.31M2026-09-02
AllianceBernstein L.P.▼ Sell752,2590.27%$85.74M2026-08-14
Squarepoint Ops LLC▼ Sell466,2940.17%$61.94M2026-08-14
Wells Fargo & Company▼ Sell462,4120.16%$61.42M2026-08-14
Citigroup Inc▲ Buy360,9010.13%$47.94M2026-08-03
Adage Capital Partners GP, L.L.C.▲ Buy321,1660.11%$42.66M2026-08-14
Gotham Asset Management, LLC▲ Buy256,4350.09%$34.06M2026-08-14
Prudential Financial Inc▼ Sell155,8540.06%$20.70M2026-08-12
Q2 2026 flow:9.28M sh bought ($1.23B)2.53M sh sold ($333.94M)net +6.75M sh (+$897.64M)
Congressional Trading Activity
18 disclosed trades · ~$217.5K est. traded value · 8 buys, 10 sells
MemberChamberStateTypeAmountTradedFiled
Julie JohnsonHouseTX32▼ Sell$1K - $15K2025-09-232026-08-05
Julie JohnsonHouseTX32▲ Buy$1K - $15K2025-09-232026-08-05
Lisa McClainHouseMI09▼ Sell$1K - $15K2025-07-162025-08-13
Lisa McClainHouseMI09▲ Buy$1K - $15K2025-06-172025-08-13
Rob BresnahanHousePA08▲ Buy$1K - $15K2025-05-152025-05-31
Jefferson ShreveHouseIN06▼ Sell$15K - $50K2025-05-122025-06-22
Jefferson ShreveHouseIN06▲ Buy$15K - $50K2025-04-172025-05-08
Rob BresnahanHousePA08▼ Sell$1K - $15K2025-04-082025-04-28
Julie JohnsonHouseTX32▼ Sell$1K - $15K2025-04-012025-05-14
Jefferson ShreveHouseIN06▼ Sell$15K - $50K2025-03-132025-04-11
Julie JohnsonHouseTX32▼ Sell$1K - $15K2025-03-032025-04-14
Tommy TubervilleSenateAL▼ Sell$1K - $15K2024-05-032026-08-05
Tommy TubervilleSenateAL▲ Buy$1K - $15K2024-04-052024-05-15
Tommy TubervilleSenateAL▼ Sell$1K - $15K2023-10-162023-11-16
Tommy TubervilleSenateAL▲ Buy$1K - $15K2023-04-032023-05-12
Tommy TubervilleSenateAL▲ Buy$1K - $15K2022-04-032023-05-11
Sheldon WhitehouseSenateRI▼ Sell$1K - $15K2015-02-242015-03-17
Sheldon WhitehouseSenateRI▲ Buy$1K - $15K2014-10-022015-08-12